{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:54:14Z","timestamp":1715993654137},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11899-008-0009-7","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T14:14:04Z","timestamp":1201702444000},"page":"54-60","source":"Crossref","is-referenced-by-count":2,"title":["Eradication of minimal residual disease in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"3","author":[{"given":"Carmen Diana","family":"Schweighofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","unstructured":"Binet JL, Lepoprier M, Dighiero G, et al.: A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977, 40:855-864.","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJM200012143432410","volume":"343","author":"G. Dighiero","year":"2000","unstructured":"Dighiero G, Binet J-L: When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799\u20131801.","journal-title":"N Engl J Med"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"K.R. Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219\u2013234.","journal-title":"Blood"},{"key":"9_CR4","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M. Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764\u20131775.","journal-title":"N Engl J Med"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H. Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910\u20131916.","journal-title":"N Engl J Med"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"T.J. Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848\u20131854.","journal-title":"Blood"},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"A.C. Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M, et al.: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21:956\u2013964.","journal-title":"Leukemia"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","volume":"18","author":"S. Bottcher","year":"2004","unstructured":"Bottcher S, Ritgen M, Pott C, et al.: Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637\u20131645.","journal-title":"Leukemia"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C. Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Colomer D, et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563\u20134569.","journal-title":"Blood"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"A.C. Rawstron","year":"2001","unstructured":"Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29\u201335.","journal-title":"Blood"},{"key":"9_CR11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D. Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230\u2013239.","journal-title":"Lancet"},{"key":"9_CR12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"B.F. Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hop finger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885\u2013891.","journal-title":"Blood"},{"key":"9_CR13","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"K.R. Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750\u20131757.","journal-title":"N Engl J Med"},{"key":"9_CR14","first-page":"1662","volume":"91","author":"M. Brugiatelli","year":"2006","unstructured":"Brugiatelli M, Bandini G, Barosi G, et al.: Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006, 91:1662\u20131673.","journal-title":"Haematologica"},{"key":"9_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","volume":"80","author":"L.E. Robertson","year":"1992","unstructured":"Robertson LE, Huh YO, Butler JJ, et al.: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80:29\u201336.","journal-title":"Blood"},{"key":"9_CR16","first-page":"860","volume":"91","author":"K. Maloum","year":"2006","unstructured":"Maloum K, Charlotte F, Divine M, et al.: A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia. Haematologica 2006, 91:860\u2013861.","journal-title":"Haematologica"},{"key":"9_CR17","unstructured":"Cazin B, Maloum K, Creteil M, et al.: Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients [abstract 1598]. Presented at the 45th annual meeting of the American Society of Hematology. San Diego; December 6\u20139, 2003."},{"key":"9_CR18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","volume":"119","author":"F. Bosch","year":"2002","unstructured":"Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002, 119:976\u2013984.","journal-title":"Br J Haematol"},{"key":"9_CR19","unstructured":"Bosch F, Ferrer A, Villamor N, et al.: Combination chemotherapy with fludarabine, cyclophosphamide and mitoxantrone (FCM) induces a high response rate in previously untreated CLL [abstract 718]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10\u201313, 2005."},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"M.J. Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079\u20134088.","journal-title":"J Clin Oncol"},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","volume":"106","author":"C.S. Tam","year":"2006","unstructured":"Tam CS, Wolf M, Prince HM, et al.: Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006, 106:2412\u20132420.","journal-title":"Cancer"},{"key":"9_CR22","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al.: Extended follow-up of a chemo-immunotherapy regimen FCR (fludarabine, F; cyclophosphamide, C; and rituximab, R) as initial therapy for chronic lymphocytic leukemia (CLL) [abstract 2118]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10\u201313, 2005."},{"key":"9_CR23","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W. Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070\u20134078.","journal-title":"J Clin Oncol"},{"key":"9_CR24","doi-asserted-by":"crossref","unstructured":"Faderl S, Wierda WG, O\u2019Brien S, et al.: Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: results of a phase 2 study [abstract 2836]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9\u201312, 2006.","DOI":"10.1182\/blood.V108.11.2836.2836"},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G. Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278\u20133281.","journal-title":"Blood"},{"key":"9_CR26","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P. Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971\u20132979.","journal-title":"J Clin Oncol"},{"key":"9_CR27","first-page":"1435","volume":"90","author":"N.C. Osuji","year":"2005","unstructured":"Osuji NC, Del Giudice I, Matutes E, et al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90:1435\u20131436.","journal-title":"Haematologica"},{"key":"9_CR28","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Winkler D, Krober A, et al.: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) [abstract 478]. Presented at the 46th annual meeting of the American Society of Hematology. San Diego; December 4\u20137, 2004.","DOI":"10.1182\/blood.V104.11.478.478"},{"key":"9_CR29","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"M.J. Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554\u20133561.","journal-title":"Blood"},{"key":"9_CR30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J. Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768\u2013773.","journal-title":"Blood"},{"key":"9_CR31","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A. Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567\u20131574.","journal-title":"J Clin Oncol"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A. Osterborg","year":"1996","unstructured":"Osterborg A, Fassas AS, Anagnostopoulos A, et al.: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996, 93:151\u2013153.","journal-title":"Br J Haematol"},{"key":"9_CR33","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","volume":"104","author":"G. Hale","year":"2004","unstructured":"Hale G, Rebello P, Brettman LR, et al.: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004, 104:948\u2013955.","journal-title":"Blood"},{"key":"9_CR34","unstructured":"Mayer J, Robak T, Skotnicki A, et al.: Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for Bcell chronic lymphocytic leukemia (BCLL) [abstract 7035]. Presented at the 43th annual meeting of the American Society of Clinical Oncology. Chicago; June 1\u20135, 2007."},{"key":"9_CR35","doi-asserted-by":"crossref","unstructured":"Hillmen P, Skotnicki A, Robak T, et al.: Alemtuzumab (Campath(R), MabCampath(R)) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract 301]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9\u201312, 2006.","DOI":"10.1182\/blood.V108.11.301.301"},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","volume":"23","author":"T. Elter","year":"2005","unstructured":"Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024\u20137031.","journal-title":"J Clin Oncol"},{"key":"9_CR37","doi-asserted-by":"crossref","unstructured":"Tedeschi A, Montillo M, Miqueleiz S, et al.: Combination of fludarabine (FAMP), cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL) [abstract 5036]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10\u201313, 2005.","DOI":"10.1182\/blood.V106.11.5036.5036"},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13693780400007151","volume":"46","author":"P. Smolewski","year":"2005","unstructured":"Smolewski P, Szmigielska-Kaplon A, Cebula B, et al.: Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005, 46:87\u2013100.","journal-title":"Leuk Lymphoma"},{"key":"9_CR39","unstructured":"Wierda WG, O\u2019Brien S, Faderl S, et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract 31]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9\u201312, 2006."},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2141.1997.1062924.x","volume":"97","author":"M.J. Dyer","year":"1997","unstructured":"Dyer MJ, Kelsey SM, Mackay HJ, et al.: In vivo \u2018purging\u2019 of residual disease in CLL with Campath-1H. Br J Haematol 1997, 97:669\u2013672.","journal-title":"Br J Haematol"},{"key":"9_CR41","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","volume":"98","author":"S.M. O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SM, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657\u20132663.","journal-title":"Cancer"},{"key":"9_CR42","unstructured":"Wierda WG, Kipps TJ, Keating MJ, et al.: Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL [abstract 2839]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9\u201312, 2006."},{"key":"9_CR43","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","volume":"24","author":"M. Montillo","year":"2006","unstructured":"Montillo M, Tedeschi A, Miqueleiz S, et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006, 24:2337\u20132342.","journal-title":"J Clin Oncol"},{"key":"9_CR44","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","volume":"18","author":"C.M. Wendtner","year":"2004","unstructured":"Wendtner CM, Ritgen M, Schweighofer CD, et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18:1093\u20131101.","journal-title":"Leukemia"},{"key":"9_CR45","doi-asserted-by":"crossref","unstructured":"Ritgen M, Schweighofer C, Fingerle-Rowson G, et al.: Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions-update on a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract 2506]. Presented at the 46th annual meeting of the American Society of Hematology. San Diego; December 4\u20137, 2004.","DOI":"10.1182\/blood.V104.11.2506.2506"},{"key":"9_CR46","doi-asserted-by":"crossref","unstructured":"Schweighofer C, Ritgen M, Eichhorst B, et al.: Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission-long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract 33]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9\u201312, 2006.","DOI":"10.1182\/blood.V108.11.33.33"},{"key":"9_CR47","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404435","volume":"20","author":"C. Karlsson","year":"2006","unstructured":"Karlsson C, Norin S, Kimby E, et al.: Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006, 20:2204\u20132207.","journal-title":"Leukemia"},{"key":"9_CR48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","volume":"21","author":"P. Dreger","year":"2007","unstructured":"Dreger P, Corradini P, Kimby E, et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12\u201317.","journal-title":"Leukemia"},{"issue":"Suppl1","key":"9_CR49","first-page":"S68","volume":"83","author":"P. Dreger","year":"2004","unstructured":"Dreger P: Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT. Ann Hematol 2004, 83(Suppl 1):S68\u2013S70.","journal-title":"Ann Hematol"},{"key":"9_CR50","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","volume":"106","author":"J.G. Gribben","year":"2005","unstructured":"Gribben JG, Zahrieh D, Stephans K, et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389\u20134396.","journal-title":"Blood"},{"key":"9_CR51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2006.05982.x","volume":"133","author":"D.W. Milligan","year":"2006","unstructured":"Milligan DW, Kochethu G, Dearden C, et al.: High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006, 133:173\u2013175.","journal-title":"Br J Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0009-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:56:18Z","timestamp":1684212978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0009-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}